EGFR and non-small cell lung carcinoma: Although patients with wild-type EGFR tumors may be unable to benefit from the targeted therapy of EGFR-TKI, shikonin provides an alternative solution to enhance the antitumor effect of EGFR-TKI on wild-type EGFR NSCLC.